{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:01:04Z","timestamp":1790704864587,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.phrs.2016.11.025","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T01:08:55Z","timestamp":1479863335000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: Therapeutic implications"],"prefix":"10.1016","volume":"115","author":[{"given":"Zsuzsa","family":"Szondy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pallai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.11.025_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1165\/ajrcmb\/9.5.511","article-title":"Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients","volume":"9","author":"Pfeffer","year":"1993","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2016.11.025_bib0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1359-6101(03)00022-4","article-title":"Biological functions of tumor necrosis factor cytokines and their receptors","volume":"14","author":"Pfeffer","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.phrs.2016.11.025_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/icb.2013.15","article-title":"Regulation of TNF-\u03b1 with a focus on rheumatoid arthritis","volume":"91","author":"Moelants","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0030","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/312724a0","article-title":"Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin","volume":"312","author":"Pennica","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.11.025_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0092-8674(88)90486-2","article-title":"A novel form of TNF\/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF","volume":"53","author":"Kriegler","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.11.025_bib0040","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.4049\/jimmunol.143.12.4034","article-title":"Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor","volume":"143","author":"Luettiq","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/385733a0","article-title":"Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha","volume":"385","author":"Moss","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.11.025_bib0050","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumor-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.11.025_bib0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0962-8924(00)89088-1","article-title":"Two tumour necrosis factor receptors: structure and function","volume":"5","author":"Vandenabeele","year":"1995","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0060","doi-asserted-by":"crossref","first-page":"18542","DOI":"10.1016\/S0021-9258(17)46661-0","article-title":"Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor","volume":"268","author":"Tartaglia","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.11.025_bib0065","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.11.025_bib0070","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.95.2.570","article-title":"The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor","volume":"95","author":"Grell","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.11.025_bib0075","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.11.025_bib0080","first-page":"51","article-title":"Soluble and cell surface receptors for tumor necrosis factor","volume":"35","author":"Wallach","year":"1991","journal-title":"Agents Actions Suppl."},{"key":"10.1016\/j.phrs.2016.11.025_bib0085","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1073\/pnas.89.11.4845","article-title":"Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo","volume":"89","author":"Van Zee","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.11.025_bib0090","doi-asserted-by":"crossref","first-page":"35887","DOI":"10.1074\/jbc.M112.365171","article-title":"A role for cGMP in inducible nitric-oxide synthase (iNOS)-induced tumor necrosis factor (TNF) a-converting enzyme (TACE\/ADAM17) activation translocation, and TNF receptor 1 (TNFR1) shedding in hepatocytes","volume":"287","author":"Chanthaphavong","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.11.025_bib0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55kDa TNF receptor TNFR1, define a family of dominantly inherited autoinflammatory syndromes","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.11.025_bib0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev.iy.07.040189.003205","article-title":"The biology of cachectin\/TNF\u2013a primary mediator of the host response","volume":"7","author":"Beutler","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0105","first-page":"1","article-title":"The relationship of inflammation and initiation of autoimmune disease: role of TNF super family members","volume":"266","author":"Flavell","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0110","first-page":"90","article-title":"Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action","volume":"47","author":"Feldmann","year":"1995","journal-title":"J. Inflamm."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2016.11.025_bib0115","doi-asserted-by":"crossref","first-page":"I32","DOI":"10.1136\/ard.58.2008.i32","article-title":"The function of tumour necrosis factor and receptors in models of multi-organ inflammation rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease","volume":"58","author":"Kollias","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2016.11.025_bib0120","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7927.1","article-title":"Recent advances in understanding psoriasis","volume":"5","author":"Eberle","year":"2016","journal-title":"F1000Res."},{"key":"10.1016\/j.phrs.2016.11.025_bib0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/cvr\/cvn120","article-title":"Cytokines and atherosclerosis: a comprehensive review of studies in mice","volume":"79","author":"Kleemann","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2016.11.025_bib0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12016-007-8067-5","article-title":"Wegener\u2019s granulomatosis: the current view","volume":"35","author":"Moosig","year":"2008","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2013.07.016","article-title":"Inflammatory pathways in spondyloarthritis","volume":"57","author":"Hreggvidsdottir","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.11.025_bib0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-065X.1995.tb00070.x","article-title":"Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease","volume":"144","author":"Maini","year":"1995","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2016.11.025_bib0150","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis","volume":"29","author":"den Broeder","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","article-title":"Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded randomized, dose-escalating trial","volume":"41","author":"Choy","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.phrs.2016.11.025_bib0165","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2016.11.025_bib0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/acr.20372","article-title":"Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis","volume":"63","author":"Weinblatt","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2016.11.025_bib0175","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2016.11.025_bib0180","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1136\/ard.2005.042416","article-title":"Current state of tumour necrosis factor \u03b1 blockade in Wegener\u2019s granulomatosis","volume":"64","author":"Mukhtyar","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2016.11.025_bib0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"BIOBADASER Study Group, efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2016.11.025_bib0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2016.11.025_bib0195","first-page":"45","article-title":"Treatment of ankylosing spondylitis: focus on etanercept","volume":"1","author":"Frech","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.phrs.2016.11.025_bib0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"The use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2016.11.025_bib0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/gastro\/gou087","article-title":"Optimizing the use of biological therapy in patients with inflammatory bowel disease Optimizing the use of biological therapy in patients with inflammatory bowel disease","volume":"3","author":"Moss","year":"2015","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.phrs.2016.11.025_bib0210","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-a blockade with infliximab in refractory Wegener\u2019s granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2016.11.025_bib0215","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors \u2212 state of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.phrs.2016.11.025_bib0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1759720X09359728","article-title":"Anti-TNF therapy in ankylosing spondylitis: insights for the clinician","volume":"2","author":"Coates","year":"2010","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.phrs.2016.11.025_bib0225","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2016.11.025_bib0230","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5021\/ad.2015.27.4.446","article-title":"Erythrodermic psoriasis treated with golimumab: a case report","volume":"27","author":"Lee","year":"2015","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0235","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/ndt\/gfq187","article-title":"Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement","volume":"25","author":"Laurino","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2016.11.025_bib0240","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2217\/imt.14.65","article-title":"Anti-TNF therapeutics for the treatment of sarcoidosis","volume":"6","author":"Crommelin","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.phrs.2016.11.025_bib0245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3899\/jrheum.150641","article-title":"New approaches in tumor necrosis factor antagonism for the treatment of psoriatic arthritis: certolizumab pegol","volume":"93","author":"Cauli","year":"2015","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.phrs.2016.11.025_bib0250","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2016.11.025_bib0255","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1084\/jem.180.6.2173","article-title":"Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis","volume":"180","author":"Evans","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2016.11.025_bib0260","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2016.11.025_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(89)90143-3","article-title":"Cell surface tumor necrosis factor (TNF) accounts for monocyte- and lymphocyte-mediated killing of TNF-resistant target cells","volume":"122","author":"Peck","year":"1989","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0270","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3588::AID-IMMU3588>3.0.CO;2-O","article-title":"Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity","volume":"29","author":"Caron","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0275","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4049\/jimmunol.138.3.957","article-title":"Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages","volume":"138","author":"Decker","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0280","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.4049\/jimmunol.154.6.2928","article-title":"Expression of TNF receptors by T cells and membrane TNF-alpha by alveolar macrophages suggests a role for TNF-alpha in the regulation of the local immune responses in the lung of HIV-1-infected patients","volume":"154","author":"Agostini","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0285","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/eji.1830271119","article-title":"In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis","volume":"27","author":"K\u00fcsters","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0290","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood.V86.5.1836.bloodjournal8651836","article-title":"Both tumor necrosis factor receptors TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha","volume":"86","author":"Schmid","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.11.025_bib0295","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.4049\/jimmunol.158.8.3673","article-title":"Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF alpha","volume":"158","author":"Parry","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0300","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.11.025_bib0305","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/363464a0","article-title":"Membrane tumour necrosis factor-alpha is involved in the polyclonal B-cell activation induced by HIV-infected human T cells","volume":"363","author":"Macchia","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.11.025_bib0310","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.4049\/jimmunol.1000560","article-title":"Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells","volume":"185","author":"Kleijwegt","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0315","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.4049\/jimmunol.168.7.3394","article-title":"Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Gu\u00e9rin infection in the absence of secreted TNF and lymphotoxin-alpha","volume":"168","author":"Olleros","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.phrs.2016.11.025_bib0325","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2016.11.025_bib0330","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/MIB.0b013e318280b169","article-title":"The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor \u03b1","volume":"19","author":"Ueda","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2016.11.025_bib0335","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-TNF agents on transmembrane TNF-expressing cells: comparison among infliximab, etanercept and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2016.11.025_bib0340","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/gut.2005.090464","article-title":"Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications","volume":"56","author":"Mudter","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2016.11.025_bib0345","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cytogfr.2004.03.011","article-title":"Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system","volume":"15","author":"Eissner","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.phrs.2016.11.025_bib0350","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4049\/jimmunol.166.1.130","article-title":"Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells","volume":"166","author":"Harashima","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0355","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1172\/JCI117215","article-title":"Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo","volume":"93","author":"Ferran","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.025_bib0360","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2567.2005.02190.x","article-title":"Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells","volume":"115","author":"Vudattu","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.phrs.2016.11.025_bib0365","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1189\/jlb.0208078","article-title":"Transmembrane TNF-alpha mediates forward and reverse signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells","volume":"84","author":"Zhang","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0370","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejcb.2008.09.001","article-title":"Influence of reverse signaling via membrane TNF-alpha on cytotoxicity of NK92 cells","volume":"88","author":"Yu","year":"2009","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0375","first-page":"885","article-title":"Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated \u2018reverse signaling'","volume":"18","author":"Xin","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.phrs.2016.11.025_bib0380","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.4049\/jimmunol.179.6.4239","article-title":"Interaction between transmembrane TNF and TNFR1\/2 mediates the activation of monocytes by contact with T cells","volume":"179","author":"Rossol","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0385","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","article-title":"Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages","volume":"164","author":"Eissner","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0390","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4049\/jimmunol.1501573","article-title":"Transmembrane TNF-\u03b1 reverse signaling inhibits lipopolysaccharide-Induced proinflammatory cytokine formation in macrophages by inducing TGF-\u03b2: therapeutic implications","volume":"196","author":"Pallai","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0395","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/312724a0","article-title":"Human tumour necrosis factor: precursor structure: expression and homology to lymphotoxin","volume":"312","author":"Pennica","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.11.025_bib0400","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-\u03b1","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2016.11.025_bib0405","first-page":"152","article-title":"Phosphorylation of the 26kDa TNF precursor in monocytic cells and in transfected HeLa cells","volume":"45","author":"P\u00f3csik","year":"1995","journal-title":"J. Inflamm."},{"key":"10.1016\/j.phrs.2016.11.025_bib0410","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/emboj\/18.8.2119","article-title":"A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in \u2018reverse signalling\u2019","volume":"18","author":"Watts","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2016.11.025_bib0415","first-page":"411","article-title":"Receptor-like properties of the 26kDa transmembrane form of TNF","volume":"12","author":"Domonkos","year":"2001","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.phrs.2016.11.025_bib0420","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ncb1440","article-title":"SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production","volume":"8","author":"Friedmann","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0425","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cyto.2004.06.008","article-title":"Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes","volume":"28","author":"Kirchner","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.phrs.2016.11.025_bib0430","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/gutjnl-2011-300384","article-title":"mTNF reverse signalling induced by TNF\u03b1 antagonists involves a GDF-1 dependent pathway: implications for Crohn\u2019s disease","volume":"62","author":"Derer","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2016.11.025_bib0435","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0016-5085(03)00979-X","article-title":"Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab","volume":"125","author":"Waetzig","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2016.11.025_bib0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1096\/fj.04-2073fje","article-title":"Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1","volume":"19","author":"Waetzig","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2016.11.025_bib0445","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/eji.1830240608","article-title":"Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression","volume":"24","author":"Weller","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0450","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13075-016-0955-8","article-title":"Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling","volume":"18","author":"Boyer","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2016.11.025_bib0455","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-beta regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0460","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","article-title":"Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease","volume":"359","author":"Shull","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.11.025_bib0465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00918135","article-title":"Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure","volume":"12","author":"Wahl","year":"1992","journal-title":"J. Clin. Immun."},{"key":"10.1016\/j.phrs.2016.11.025_bib0470","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.3175638","article-title":"Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta","volume":"242","author":"Gamble","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.11.025_bib0475","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/334260a0","article-title":"Deactivation of macrophages by transforming growth factor-beta","volume":"334","author":"Tsunawaki","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.11.025_bib0480","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1084\/jem.166.2.571","article-title":"Inhibition of cytokine production by cyclosporin A and transforming growth factor beta","volume":"166","author":"Espevik","year":"1987","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2016.11.025_bib0485","first-page":"164","article-title":"The granulomatous inflammatory process. A review","volume":"84","author":"Adams","year":"1976","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0490","series-title":"The Granulomatous Disorders","first-page":"3","article-title":"Biology and immunology of the granuloma","author":"Agostini","year":"1999"},{"key":"10.1016\/j.phrs.2016.11.025_bib0495","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1172\/JCI13863","article-title":"TGF-beta\/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation","volume":"108","author":"Fiocchi","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.11.025_bib0500","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s001090100263","article-title":"Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener\u2019s granulomatosis","volume":"79","author":"Murak\u00f6zy","year":"2001","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.phrs.2016.11.025_bib0505","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/5584_2014_106","article-title":"TGF-\u03b2 and SMADs mRNA expression in pulmonary sarcoidosis","volume":"852","author":"Piotrowski","year":"2015","journal-title":"Avd. Exp. Med. Biol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0510","first-page":"503","article-title":"Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn\u2019s disease","volume":"10","author":"Hartman","year":"2008","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.phrs.2016.11.025_bib0515","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0923-1811(93)90760-M","article-title":"The role of cytokines in the psoriatic inflammation","volume":"5","author":"Kapp","year":"1993","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.phrs.2016.11.025_bib0520","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.2916128","article-title":"Overexpression of transforming growth factor alpha in psoriatic epidermis","volume":"243","author":"Elder","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.11.025_bib0525","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2133.1998.02026.x","article-title":"Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis","volume":"138","author":"Leivo","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0530","first-page":"277","article-title":"Immuno pathogenesis of psoriasis: a possible role of TGF\u03b2\/Smads pathway","volume":"119","author":"Sferra","year":"2014","journal-title":"IJAE"},{"key":"10.1016\/j.phrs.2016.11.025_bib0535","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0540","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"5","author":"Arican","year":"2005","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.phrs.2016.11.025_bib0545","doi-asserted-by":"crossref","first-page":"30226","DOI":"10.1074\/jbc.M005310200","article-title":"Tumor necrosis factor-alpha inhibits transforming growth factor-beta\/Smad signaling in human dermal fibroblasts via AP-1 activation","volume":"275","author":"Verrecchia","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.11.025_bib0550","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.4049\/jimmunol.171.7.3855","article-title":"Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts","volume":"171","author":"Yamane","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0555","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2016.11.025_bib0560","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2133.2005.07078.x","article-title":"Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis","volume":"154","author":"Kr\u00fcger-Krasagakis","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0565","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.coph.2009.04.008","article-title":"Anti-inflammatory and pro-inflammatory roles of TGF-beta IL-10, and IL-22 in immunity and autoimmunity","volume":"9","author":"Sanjabi","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0570","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2249.2002.01785.x","article-title":"Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-\u03b21 in synovial fibroblasts from rheumatoid arthritis and normal individuals","volume":"127","author":"Cheon","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0575","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.173.5.1121","article-title":"Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia","volume":"173","author":"Fava","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2016.11.025_bib0580","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/ar412","article-title":"Homing chemokines in rheumatoid arthritis","volume":"4","author":"Loetscher","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.phrs.2016.11.025_bib0585","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar2337","article-title":"Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts","volume":"9","author":"M\u00fcller-Ladner","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2016.11.025_bib0590","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/intimm\/dxl128","article-title":"TGF-\u03b2 type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody","volume":"19","author":"Sakuma","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.phrs.2016.11.025_bib0595","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2005.037465","article-title":"Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor a in two patients with early disease and transforming growth factor b in three more advanced cases","volume":"55","author":"Fran\u00e7ois","year":"2006","journal-title":"Ann. Rheum. Dis."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816311707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816311707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T19:15:49Z","timestamp":1718910949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816311707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":119,"alternative-id":["S1043661816311707"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.11.025","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: Therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}